Monday, January 27, 2020

WuXi Global Forum 2020 – Advancing Breakthroughs for Patients

Now in its eighth year, the WuXi Global Forum at the J.P. Morgan Healthcare Conference brings together thousands of leaders to promote new thinking on a global stage as we strive...

WuXi ATU and GeneMedicine Sign Development and Manufacturing Agreement for Oncolytic Virus Products

Shanghai and Seoul, November 29, 2019 - WuXi ATU Co., Ltd., (WuXi ATU) - a subsidiary of WuXi AppTec, and GeneMedicine - a South Korea-based gene therapy biotechnology company,...

WuXi AppTec’s Lab Testing Division Expands Toxicology Facility in Suzhou, China

WuXi AppTec, a leading global provider of R&D and manufacturing services enabling companies in the pharmaceutical, biotechnology and medical device industries, today announced its Lab Testing Division (LTD)...

WuXi AppTec Receives 2019 Global Integrated Drug Development Competitive Strategy Innovation & Leadership Award...

WuXi AppTec, a leading global provider of R&D and manufacturing services enabling companies in the pharmaceutical, biotechnology and medical device industries, today announced that it received the 2019...

Dr. Ge Li Awarded “CEO of the Year” at CPhI Worldwide 2019

November 11, 2019: WuXi AppTec, a leading global provider of R&D and manufacturing services enabling companies in the pharmaceutical, biotechnology and medical device industries, announced today that its...

Subscribe to our Newsletter

SPOTLIGHT

STAY CONNECTED

Twitter LinkedIn 

INNOVATION THAT MATTERS

Amicus Therapeutics: A Patient-First Approach to Treating Rare Diseases

Rare diseases have long posed a dual challenge. First, since there are relatively few patients by definition, they are not the highest priority for...